Something is shifting in the European psychedelic conversation, and you can feel it in the rooms. Last week brought two of the more substantive gatherings on the continent — a mental-health summit in London with a serious thread on interventional psychiatry, and the Interdisciplinary Conference on Psychedelic Research (ICPR) in the Netherlands. Both pulled in researchers, clinicians, policy people, and a handful of patients who've actually been through these treatments. The mood was less hype than I expected. More pragmatic. More European, if that means anything.

For anyone weighing whether a psychedelic retreat or a clinical psychedelic treatment is something to pursue — and I get emails about this constantly — what's happening in Europe right now matters. The U.S. story has stalled in ways nobody quite predicted a few years back. Meanwhile, Germany has begun treating its first patients through compassionate-use psilocybin pathways. Czechia is doing its own thing. Switzerland keeps quietly doing what it's done for years. The picture for plant medicine and psychedelic-assisted therapy looks very different depending on which border you're standing at.

Here's what stood out from the two events, and what it might mean if you're sitting at a kitchen table somewhere trying to figure out if any of this is for you.

What's Actually Happening With Ex-U.S. Psychedelic Approvals

The American FDA's reluctance around MDMA-assisted therapy in 2024 created a vacuum. Some assumed the field would simply pause and wait. That hasn't happened. Instead, attention has scattered — toward Europe, Australia (which legalized prescribed MDMA and psilocybin a few years back), and a few other jurisdictions willing to move ahead of consensus.

At the London summit, the panel on interventional psychiatry in Europe kept circling back to a question regulators don't love: what counts as enough evidence? The phase 3 trials for psilocybin in treatment-resistant depression are progressing. Several European agencies are watching closely. There's a real possibility — not certainty, but a real possibility — that a regulated psilocybin product reaches European patients before it reaches American ones. That would be a remarkable inversion of how this story was supposed to go.

What I took away: if you're in your forties, you've struggled with depression for fifteen years, and you've been holding out for a clean FDA-approved psilocybin pathway, the next two or three years in Europe could open doors that the U.S. won't. Whether you'd actually travel for that is a different question.

The Psychotherapy Question Nobody Has Solved

This came up at both events, in slightly different registers. In London, the conversation was about whether psychedelic treatments require formal psychotherapy bolted on, or whether the drug itself does most of the lifting if the setting is held well. In the Netherlands, the conversation was more academic but pointed in a similar direction.

You'll hear strong opinions on both sides. The pharmaceutical companies trying to bring psilocybin or MDMA to market have an incentive to minimize the therapy component — it's expensive, hard to scale, hard to standardize. The clinicians who've actually sat with people through these experiences tend to say that the holding, the integration, the human relationship is half the medicine. Maybe more.

From what I've seen on the retreat side, this debate isn't abstract. The difference between a ceremony where someone is genuinely held — with prep beforehand, careful attention during, and real integration support after — and one where you're handed a cup and left to figure it out is enormous. People come back from the first kind changed. People come back from the second kind sometimes worse than when they arrived. If you're researching retreats, this is the variable to interrogate hardest.

Germany and Czechia: The Nontraditional Access Stories

This was the part I found most useful for readers who write to me asking, in essence, where can I actually go?

Germany has begun rolling out compassionate-use access to psilocybin for treatment-resistant depression. The first patients are being treated. The payer situation is still being worked out — who covers what, how reimbursement flows, whether private insurance plays — but the pathway exists. It's narrow, gated by psychiatric criteria, and not a retreat in any sense. It's a medical treatment delivered in a clinical setting. For some readers, that's exactly the framing they want.

Czechia is moving on a different track, with its own legislative momentum around psilocybin. Switzerland's long-standing limited-access program for MDMA, LSD, and psilocybin under physician supervision continues. The Netherlands, of course, has its truffle scene — psilocybin-containing truffles are legal there, which has built a whole ecosystem of legal psychedelic retreats that operate openly.

So when someone asks me where in Europe you can actually have a legal psychedelic experience right now, the honest answer is:

• Netherlands — legal psilocybin truffle retreats, open and accessible, varying widely in quality.
• Switzerland — physician-supervised access, very limited, generally for specific psychiatric indications.
• Germany — emerging compassionate-use psilocybin for treatment-resistant depression, clinical not retreat.
• Portugal and Spain — gray-area ayahuasca and plant-medicine retreats operating in tolerated territory.
• Czechia — evolving, watch this space.

None of this is a recommendation. It's a map. What you do with it depends on what you're actually looking for — a clinical treatment for a diagnosed condition, a ceremonial encounter with master plants like ayahuasca, or something in between.

What the European Conversation Gets Right

One thing struck me across both events. The European framing of psychedelics tends to be less utopian than the American one. Less talk of revolution, more talk of harm reduction, indication-specific evidence, and patient pathways. Less Burning Man, more Bundesgesundheitsministerium.

I think this is healthy. The psychedelics-cure-everything narrative did real damage by setting expectations no medicine can meet. When someone shows up to an ayahuasca ceremony expecting their addiction to vanish in one night because they read a viral essay, and it doesn't, they leave demoralized. The European clinicians I heard from were careful. They talked about response rates, not miracles. They talked about who psychedelic-assisted recovery is probably not appropriate for — people with personal or family histories of psychosis, certain cardiac conditions, certain medications that interact dangerously.

That caution doesn't dampen the genuine promise. Psilocybin for treatment-resistant depression keeps producing interesting results. Ibogaine for opioid addiction continues to draw serious researchers despite the cardiac risk profile. MDMA for PTSD remains, to my eye, one of the more important clinical developments of the last decade even with the FDA setback. The promise is real. It's just narrower and more conditional than the loudest voices suggest.

If You're Trying to Decide Whether a Retreat Is Right for You

A few honest questions to sit with, drawn from what I keep hearing from people who've done this well — and from those who haven't:

1. What are you actually hoping for? Addiction recovery, trauma work, a stuck-life-pattern reset, curiosity, spiritual exploration? Different goals point toward different containers.
2. Are you medically and psychiatrically clear? Any reputable retreat will screen you carefully. If they don't, that's the red flag.
3. Do you have integration support lined up? A good experience without integration often fades. A difficult experience without integration can leave a mark. Therapists who understand psychedelic work are increasingly findable, even outside major cities.
4. Can you afford the time off afterward? Going back to a demanding job two days after a heavy ceremony is a recipe for losing whatever you gained.
5. Have you spoken with someone who's actually been? Not influencers. Real people, ideally a few of them, ideally not all from the same retreat's testimonial page.

The honest truth is that plant medicine and psychedelic retreats sit somewhere on a spectrum between profoundly useful and genuinely risky, and where any particular retreat falls depends almost entirely on the people running it, the screening they do, and the support they provide on either side of the ceremony itself. The substance matters less than the container.

For readers who want to explore further, a range of ayahuasca and psychedelic retreats from operators across the field can be browsed on our marketplace here. Take your time with the decision — the conversations happening in London and the Netherlands suggest the landscape will keep widening, and there's rarely a good reason to rush.